Testosterone side effects in women are the safety test of the whole treatment plan.
In a 2019 systematic review and meta-analysis of 36 randomized trials with 8,480 participants, testosterone improved sexual-function outcomes in postmenopausal women, including 0.85 more satisfactory sexual events on average versus placebo or comparator therapy. The same review found more androgenic effects such as acne and hair growth, and oral testosterone had worse lipid effects than non-oral routes. [1]
That is the balanced starting point: benefit can be real, but the indication, product, dose, blood level, and side effects decide whether treatment still fits.
Bottom line
Testosterone for women is not female TRT and not a general midlife optimization drug. The Global Consensus Position Statement says the only evidence-based indication is hypoactive sexual desire disorder in postmenopausal women after formal biopsychosocial assessment. [2]
International Society for the Study of Women's Sexual Health guidance gives the practical safety frame: systemic transdermal testosterone can be considered for hypoactive sexual desire disorder not mainly caused by modifiable factors or comorbidities, total testosterone should be checked before treatment as a baseline for monitoring, and dosing should keep levels within the physiologic premenopausal female range. [3]
The evidence is limited in a way that matters for side effects. Trials support sexual-function outcomes in selected postmenopausal women, but long-term safety is not established, and the evidence does not justify supraphysiologic dosing, pellets as routine, unclear compounded products, or use for fatigue, weight, mood, cognition, muscle, or anti-aging goals. [2] [3] [4]
What testosterone side effects in women after menopause matter most?
Acne and unwanted hair growth are the side effects with the clearest randomized-trial signal. Voice change, clitoral symptoms, severe acne, rapid facial hair progression, unexpectedly high testosterone, or rapid scalp hair changes are higher-concern signals because they can suggest excess androgen exposure or the wrong product/dose. [1] [3]
| Side effect or finding | What it may signal | What should happen |
|---|---|---|
| Acne or oily skin | Androgen effect or poor dose tolerance. | Review dose, level, product, application, and whether benefit justifies continuing. [1] |
| New facial or body hair growth | Trial-supported androgenic effect. | Track severity; consider dose reduction or stopping if progressive. [1] |
| Scalp shedding or widening part | Could be androgen sensitivity, female-pattern hair loss, telogen effluvium, thyroid, ferritin, medication, or weight-loss related. | Do not assume; do a hair-loss pattern and trigger review. |
| Voice deepening | Serious androgen-excess signal; may not fully reverse. | Prompt clinician review before continuing or increasing dose. [3] |
| Clitoral symptoms or enlargement | Serious androgen-excess signal. | Prompt review and likely dose/product reassessment. [3] |
| Mood activation, irritability, or sleep disruption | Dose, comorbidity, medication, or non-testosterone cause may matter. | Reassess diagnosis and treatment goal. |
| Lipid worsening | Especially relevant with oral testosterone. | Avoid oral routes for routine hypoactive sexual desire disorder use; review lipid and cardiovascular risk. [1] |
| No desire/distress improvement | Lab change without meaningful symptom benefit is not success. | Stop or change plan based on predefined endpoint. |
Scalp hair deserves a separate evaluation
It is too simple to say testosterone reliably causes hair loss in women. It is also too simple to dismiss scalp changes as unrelated.
Female-pattern hair loss can be androgen-sensitive, but midlife shedding can also come from low ferritin, thyroid disease, rapid weight loss, illness, surgery, stress, medications, inflammatory scalp disease, traction, or frontal fibrosing alopecia. A woman can have hypoactive sexual desire disorder and a separate hair-loss diagnosis at the same time.
The better question is: did acne, facial hair, scalp shedding, or a widening part appear or worsen after testosterone exposure, and is the blood level still in the female physiologic range? If the answer is unclear, dose escalation should wait.
Product choice changes side-effect risk
Most testosterone products in the United States are labeled for men, not women. DailyMed testosterone gel labeling states that the product is not indicated for use in women and includes warnings about secondary exposure from contact with the application site. [5]
Guidelines still allow carefully monitored off-label use in women with hypoactive sexual desire disorder, but that is different from casual use of male-dose products. Small dosing errors can matter more because the target exposure is much lower.
| Product or route issue | Why it matters |
|---|---|
| Doseable transdermal route | Guidelines generally prefer adjustable non-oral dosing for women with hypoactive sexual desire disorder. [3] [4] |
| Oral testosterone | The 2019 meta-analysis found worse lipid effects with oral testosterone than non-oral routes. [1] |
| Pellets | Harder to rapidly adjust once inserted; ALEG 2025 says pellets are not recommended because of supraphysiologic dosing risk and insufficient evidence. [4] |
| Compounded products | International Society for the Study of Women's Sexual Health says compounded products cannot be recommended due to lack of efficacy and safety data. [3] |
| Male-dose gel or cream | Dosing and accidental transfer risk become central safety issues. [5] |
| Injections | Peaks, troughs, and dosing precision can create monitoring problems in women. |
The operational standard is not "natural" or "bioidentical." It is doseable, monitorable, physiologic-range exposure with measurable hypoactive sexual desire disorder benefit.
Monitoring timeline
Monitoring is not a bureaucratic add-on. It is how clinicians prevent a modest sexual-function benefit from becoming supraphysiologic androgen exposure.
| Timing | What to check | Why |
|---|---|---|
| Before treatment | hypoactive sexual desire disorder assessment, relationship/mental-health/medication/genitourinary syndrome of menopause contributors, total testosterone baseline, product plan, side-effect baseline. [3] | Testosterone level is used for baseline and safety monitoring, not as a stand-alone diagnosis. |
| Early follow-up | Total testosterone and side effects, often within the first 3 to 6 weeks in contemporary guidance. [4] | Exposure may be too high before benefit is fully clear. |
| Benefit checkpoint | Desire, distress, satisfying sexual events, arousal/orgasm concerns, and partner/relationship context when relevant. [1] [3] | Continue only if the target symptom improves enough to justify risk. |
| Ongoing follow-up | Acne, hair growth, scalp hair, voice, clitoral symptoms, mood, lipids or liver context when relevant, dose, application transfer risk. [1] [3] [5] | Side effects can emerge after the initial start. |
| No meaningful benefit | Stop or reassess rather than chasing higher levels. | The endpoint is symptom benefit without androgen excess, not a bigger lab number. |
Who this fits, and who should avoid shortcutting
This page fits a woman who is considering testosterone for postmenopausal hypoactive sexual desire disorder, already using testosterone and noticing acne or hair changes, or trying to decide whether a clinic's testosterone plan is appropriately monitored.
It also fits women who have overlapping concerns: low desire plus acne, facial hair, scalp thinning, polycystic ovary syndrome history, dehydroepiandrosterone use, pellets, compounded hormones, oral testosterone, injections, or a clinic aiming for "optimized" levels above the usual female range.
It is a poor fit for self-directed dose changes, product sharing, male-dose gels, pellet marketing without monitoring, or testosterone prescribed mainly for energy, confidence, fat loss, cognition, or anti-aging.
Red flags that should change the plan
Prompt clinician review is needed for voice deepening, clitoral symptoms, very high testosterone, severe or rapidly worsening acne, rapidly increasing facial hair, sudden scalp hair changes, severe mood change, abnormal lipids, liver disease complexity, pregnancy possibility, hormone-sensitive cancer history, or any product with unclear dose.
Also slow down if the original goal has drifted. If the treatment began as hypoactive sexual desire disorder care but now the dose is being raised for workouts, weight loss, mood, or a higher lab number, the plan has moved outside the evidence-supported category.
What to ask a clinician
- Is testosterone being used for formally assessed hypoactive sexual desire disorder, or has the goal shifted to fatigue, weight, mood, muscle, cognition, or anti-aging?
- What product and dose are being used, and can it be adjusted quickly if acne, hair growth, voice change, or high levels appear?
- What was my baseline total testosterone, and when will it be rechecked to avoid supraphysiologic exposure?
- Which side effects mean I should stop, lower the dose, or be seen promptly?
- Are my acne, facial hair, or scalp changes new after testosterone, or were they present before treatment?
- Are dehydroepiandrosterone, pellets, compounded hormones, oral testosterone, injections, or male-dose products increasing my risk?
- If desire-related distress is not meaningfully better by the agreed checkpoint, when do we stop?
The Endocrine Society guideline is also a safety frame: it recommends against broad androgen prescribing for general well-being, cardiometabolic health, cognition, or nonspecific low-androgen symptoms, so side effects should not be accepted for a weak treatment target. [6]
How the assessment helps
A structured assessment can organize hypoactive sexual desire disorder fit, product and dose, baseline testosterone, follow-up timing, acne, facial or body hair growth, scalp shedding, voice or clitoral symptoms, mood shifts, lipid or liver context, and accidental-transfer risk so a clinician can decide whether monitoring, dose reduction, product change, or stopping belongs in the plan. It is not a side-effect diagnosis by itself.
Related reading:
- Testosterone therapy for women after menopause.
- Testosterone blood tests after menopause.
- Testosterone and hair loss in women.
- Testosterone gel and cream for women.
- dehydroepiandrosterone vs testosterone after menopause.
References
[1] Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/s2213-8587(19)30189-5 https://pubmed.ncbi.nlm.nih.gov/31353194/
[2] Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429-434. doi:10.1080/13697137.2019.1637079 https://pubmed.ncbi.nlm.nih.gov/31474158/
[3] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2020.10.009 https://pubmed.ncbi.nlm.nih.gov/33814355/
[4] Pilnik S, Belardo A, Marchesan LB, et al. Androgen therapy in midlife and older women: a position statement of the Latin American Association of Gynecological Endocrinology (ALEG). Climacteric. 2025;28(5):529-536. doi:10.1080/13697137.2025.2548805 https://pubmed.ncbi.nlm.nih.gov/40919649/
[5] DailyMed testosterone gel 1.62% label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54fcdcb9-fb0e-4164-9e51-f2a5feae3217
[6] Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-510. doi:10.1210/jc.2014-2260 https://pubmed.ncbi.nlm.nih.gov/25279570/